Dr. Witte's lab, along with a team of researchers at UCLA, discovered three previously unidentified T-cell receptors that naturally target prostate cancer.
This study sheds light on the cause of an emerging group of endocrine autoimmune diseases that occur in patients treated with checkpoint immunotherapy.